The Effect of Resistance Training on Sarcopenia in Older Heart Failure Patients

Launched by KIEU NGUYEN DANG PHUONG · Jan 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how an eight-week resistance training program using machines can help older adults with heart failure who are also experiencing sarcopenia, a condition characterized by loss of muscle mass and strength. The goal is to see if this type of exercise can improve their overall health and well-being. The trial is currently recruiting participants aged 60 and older who have been diagnosed with both heart failure and sarcopenia, based on specific criteria related to muscle mass, strength, and physical performance.

If you or a family member qualify, you can expect to participate in a structured exercise program while receiving support and supervision. However, certain health conditions may prevent participation, such as unstable heart conditions or recent serious medical events. Participants will need to understand the study's purpose and sign a consent form agreeing to take part. This research aims to find better ways to help older adults with heart failure maintain their strength and improve their quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥ 60 years old
• • Meet the diagnostic criteria of 2019 AWGS2 sarcopenia, can be diagnosed once meeting (1) + (2) or (1) + (3) or (1) + (2) + (3): (1) Appendicular skeletal muscle mass (ASM): dual-energy X-ray absorptiometry (DXA) (male \<7.0 kg/m², female \<5.7 kg/m²). (2) Muscle strength: handgrip strength (male \<28.0 kg, female \<18.0 kg). (3) Physical performance: 6-meter walking speed \<1.0 m/s.
• • Meet the diagnostic criteria of heart failure following ESC 2021.
• • Clearly understand the content and purpose of the study and sign the informed consent form.
• Exclusion Criteria: There are contraindications for Exercise Testing in patients with stable heart failure according to ACSM 2022:
• • Early stage after acute coronary syndrome (within the first 2 days)
• • Unstable coronary artery disease
• • Decompensated heart failure
• • Acute venous thrombosis or recent arterial embolism (pulmonary or systemic)
• • Acute myocarditis, pericarditis, endocarditis
• • Aortic dissection of the valve
• • Severe symptomatic aortic stenosis
• • Acute systemic disease or fever
• • Uncontrolled or life-threatening atrial or ventricular arrhythmias (including new-onset atrial fibrillation or flutter)
• • Uncontrolled tachycardia (resting heart rate \> 120 beats per minute)
• • Third-degree AV block
• • Uncontrolled diabetes
• • Symptomatic orthostatic hypotension (\> 20 mmHg)
• • Gradually increasing fatigue during exercise or dyspnea at rest or with exertion within the past 3-5 days
• • Significant myocardial ischemia at low workloads \< 2 METs or 50W
• * Relative contraindications according to ACSM 2022:
• • Weight gain ≥ 1.8 kg in the past 1-3 days
• • Simultaneous use of continuous or intermittent Dobutamine
• • Decrease in blood pressure with exercise
• • NYHA IV heart failure
• • Complex ventricular arrhythmias at rest or with exertion
• • Resting heart rate ≥ 100 bpm when lying down
• • Comorbidities that limit exercise
• • Severe obstructive hypertrophic cardiomyopathy
• • Have participated in a cardiovascular rehabilitation program within the last 6 months
• • Do not agree to participate in the study